{
    "study_accession": "SDY674",
    "actual_completion_date": null,
    "actual_enrollment": 10,
    "actual_start_date": "2006-12-01",
    "age_unit": "Years",
    "brief_description": "This study evaluates whether belatacept and a combination of anti-rejection drugs prevents  non-human leukocyte antigen identical renal transplant rejection allowing safe anti-rejection therapy withdrawal one year post-transplant",
    "brief_title": "Vincenti ITN023ST:  Belatacept to Prevent Organ Rejection in Kidney Transplant Patients",
    "clinical_trial": "Y",
    "condition_studied": "Renal Transplant",
    "dcl_id": 2,
    "description": "Participants, at the time of transplant, begin immunosuppressive treatment with belatacept, sirolimus and thymoglobulin.  Dose reduction of belatacept begins at 12 weeks post-transplant.  Drug withdrawal begins at year 2.",
    "doi": "10.21430/M3W336PE8D",
    "endpoints": "Incidence of acute rejection at 24 weeks post transplant, graft survival, tolerance induction",
    "gender_included": "Not Specified",
    "hypothesis": "The combined use of belatacept with other immunesuppressive treatments prevents renal tranplant rejection and allows for withdrawal of immunosuppressive treatment one year post transplant",
    "initial_data_release_date": "2015-12-14",
    "initial_data_release_version": "DR16",
    "intervention_agent": "Belatacept",
    "latest_data_release_date": "2016-02-05",
    "latest_data_release_version": "DR17",
    "maximum_age": "65",
    "minimum_age": "18",
    "objectives": "Determine whether belatacept combined with other immunosuppressive treatments can prevent organ rejection in first-time renal transplant patients and allow patients to be withdrawn from anti-rejection therapy after 1 year post transplant",
    "official_title": "The Safety and Efficacy of Belatacept, Antithymocyte Globulin, and Sirolimus in Recipients of Non-HLA-identical Living-donor Renal Transplants (ITN023ST)",
    "sponsoring_organization": "NIAID",
    "target_enrollment": 30,
    "workspace_id": 4117,
    "research_focus": [
        "Transplantation"
    ],
    "arm": [
        {
            "arm_accession": "ARM2944",
            "description": "Treatment following immunosuppressive protocol including belatacept, glucocorticoids, antithymocyte globulin and sirolimus",
            "name": "Belatacept treatment"
        },
        {
            "arm_accession": "ARM2946",
            "description": "Non-HLA identical related living donor",
            "name": "Donor"
        }
    ],
    "personnel": [
        {
            "first_name": "Flavio",
            "last_name": "Vincenti",
            "organization": "University of California, San Francisco",
            "role_in_study": "Principal Investigator",
            "site_name": "University of California, San Francisco"
        }
    ],
    "pubmed": [
        {
            "title": "Costimulation blockade with belatacept in renal transplantation.",
            "journal": "N Engl J Med.",
            "month": "Aug",
            "year": "2005",
            "doi": "-",
            "pubmed_id": "16120857"
        }
    ],
    "program": [
        {
            "program_name": "ITN: Collaborative Network for Clinical Research on Immune Tolerance Network",
            "contract_name": "Immune Tolerance Network"
        }
    ],
    "assay": [],
    "subject": {
        "race": [
            {
                "race": "White",
                "count": 10
            }
        ],
        "gender": [
            {
                "Not Specified": 10
            }
        ]
    }
}
